Acticor Biotech

About the deal

Paris, France, November 28, 2023 – 8:00 am CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT – the «  »Company » »), a clinical-stage biotechnology company developing glenzocimab, a novel drug for the treatment of cardiovascular emergencies, in particular stroke, announces today the completion of its capital increase for a total gross amount of approximately 2.6 million euros, by issuing 850,360 new shares at a price of €3 per share.

The funds raised will enable the Company to strengthen its financial structure and finance its operations until May 2024, based on the following elements on the following basis:
• Net cash and cash equivalents (including bank overdrafts) amounting to € 7,955 K at June 30, 2023;
• Cash consumption by the Company’s operations in the second half of 2023, and projected cash consumption forecasts for 2024;
• Ability of the Company to pre-finance its 2023 CIR;
• The Company’s ability to modulate its variable operating expenses as part of its trials.